FRA
JAZZ icon

Front Row Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Front Row Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23K Hold
9
– – ﹤0.01% 503
2026
Q1 		$1.7K Hold
9
– – ﹤0.01% 506
2025
Q4 		$1.53K Hold
9
– – ﹤0.01% 501
2025
Q3 		$1.19K Sell
9
-4
-31% -$480 ﹤0.01% 505
2025
Q2 		$1.38K Sell
13
-8
-38% -$869 ﹤0.01% 490
2025
Q1 		$2.61K Hold
21
– – ﹤0.01% 438
2024
Q4 		$2.59K Hold
21
– – ﹤0.01% 436
2024
Q3 		$2.34K Sell
21
-51
-71% -$5.59K ﹤0.01% 440
2024
Q2 		$7.68K Sell
72
-9
-11% -$989 ﹤0.01% 641
2024
Q1 		$9.75K Buy
81
+60
+286% +$7.35K ﹤0.01% 595
2023
Q4 		$2.58K Sell
21
-50
-70% -$6.24K ﹤0.01% 405
2023
Q3 		$9.19K Hold
71
– – ﹤0.01% 540
2023
Q2 		$9K Hold
71
– – ﹤0.01% 545
2023
Q1 		$10K Buy
71
+27
+61% +$3.99K ﹤0.01% 531
2022
Q4 		$7K Sell
44
-4
-8% -$586 ﹤0.01% 566
2022
Q3 		$6K Sell
48
-10
-17% -$1.52K ﹤0.01% 613
2022
Q2 		$9K Buy
58
+6
+12% +$924 ﹤0.01% 534
2022
Q1 		$8K Hold
52
– – ﹤0.01% 596
2021
Q4 		$7K Buy
52
+12
+30% +$1.58K ﹤0.01% 667
2021
Q3 		$5K Hold
40
– – ﹤0.01% 738
2021
Q2 		$5K Sell
40
-1
-2% -$173 ﹤0.01% 741
2021
Q1 		$7K Sell
41
-1
-2% -$165 ﹤0.01% 638
2020
Q4 		$7K Hold
42
– – ﹤0.01% 613
2020
Q3 		$6K Buy
42
+3
+8% +$372 ﹤0.01% 641
2020
Q2 		$4K Sell
39
-1
-3% -$111 ﹤0.01% 694
2020
Q1 		$4K Hold
40
– – ﹤0.01% 666
2019
Q4 		$6K Sell
40
-2
-5% -$272 ﹤0.01% 575
2019
Q3 		$5K Buy
42
+10
+31% +$1.34K ﹤0.01% 598
2019
Q2 		$5K Hold
32
– – ﹤0.01% 580
2019
Q1 		$5K Buy
32
+14
+78% +$1.83K ﹤0.01% 586
2018
Q4 		$2K Hold
18
– – ﹤0.01% 791
2018
Q3 		$3K Buy
+18
New +$3.1K ﹤0.01% 694

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

Front Row Advisors's JAZZ Position: Q2 2026 in Review

Front Row Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q2 2026 at 9 shares worth $2.23K. The position accounts for ﹤0.01% of the portfolio, ranked #503.

Front Row Advisors first reported a position in JAZZ in Q3 2018 and has held it in 32 quarters since. The position peaked at $10K in Q1 2023. 641 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

  • Front Row Advisors held 9 shares of Jazz Pharmaceuticals worth $2.23K as of Q2 2026.
  • Front Row Advisors left its Jazz Pharmaceuticals share count unchanged in Q2 2026.
  • Jazz Pharmaceuticals made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #503 holding.
  • Front Row Advisors first reported a position in Jazz Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
  • Front Row Advisors's Jazz Pharmaceuticals position peaked at $10K in Q1 2023.
  • 641 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.